Introduction
============

Metabolic acidosis is a common complication of chronic kidney disease (CKD) and can lead to bone mineral loss, protein wasting, progression of renal dysfunction, and higher mortality risk \[[@b1-krcp-38-326]--[@b3-krcp-38-326]\]. Therefore, early detection and accurate diagnosis of metabolic acidosis are important to prevent CKD progression and increased risk of mortality.

In Japan, blood-gas analyzers are available in most hospitals. Therefore, clinical practice guidelines for CKD recommend measurement of bicarbonate ions (HCO~3~^−^) using samples of arterial/venous blood gases for assessment of metabolic acidosis in pre-dialysis CKD patients \[[@b4-krcp-38-326]\]. However, for these blood-gas analyses, a specific measurement device and syringe are required in addition to the blood samples used for biochemical analyses \[[@b5-krcp-38-326]\].

Serum total carbon-dioxide concentration (serum total CO~2~) can be measured readily, along with creatinine, urea, and electrolytes, using a biochemical analyzer in clinical settings \[[@b6-krcp-38-326]\]. Furthermore, values based on this measurement have been shown to be correlated strongly with HCO~3~^−^ concentration in patients without renal impairment \[[@b7-krcp-38-326]\]. However, few studies have examined the relationship between serum total CO~2~ and HCO~3~^−^ concentration in patients with renal impairment. Therefore, we analyzed the relationship between these two parameters in CKD patients who were not undergoing renal replacement therapy. Furthermore, we developed a new formula for approximation of HCO~3~^−^ concentration using clinical parameters that included serum total CO~2~ and evaluated the diagnostic accuracy of the approximated values derived from this new formula.

Methods
=======

Ethical approval of the study protocol
--------------------------------------

This study was carried out in accordance with the ethical principles contained within the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Saitama Medical Center, Jichi Medical University (No. S17-052; Saitama, Japan). The requirement of informed consent was waived, and an opt-out method was used due to the retrospective design of the study.

Inclusion and exclusion criteria
--------------------------------

Inclusion criteria were (i) age \> 20 years; (ii) stable out-patient with CKD stage G1 to 5; and (iii) simultaneous measurement of serum total CO~2~ and HCO~3~^−^ concentration. Exclusion criteria were patients (i) undergoing dialysis therapy and (ii) who had undergone renal transplantation.

Study design
------------

This was a single-center, retrospective, cross-sectional study. We analyzed patient data obtained from medical records from the Division of Nephrology, Saitama Medical Center, between April 2016 and March 2018. Laboratory data of blood tests and blood-gas tests obtained simultaneously were used for analyses.

The relationship between serum total CO~2~ and HCO~3~^−^ concentration was analyzed using Pearson's correlation coefficient. An approximation formula was developed by multiple linear regression analysis with independent factors correlated with HCO~3~^−^ concentration. The relationship between HCO~3~^−^ concentration approximated by our formula and actual HCO~3~^−^ concentration was analyzed using Pearson's correlation coefficient. The diagnostic accuracy of serum total CO~2~ and approximated HCO~3~^−^ concentration for low and high bicarbonate levels was analyzed using receiver operating characteristic (ROC) curve analysis and a 2 × 2 table.

Laboratory methods
------------------

Blood and urinary parameters were determined by the Department of Clinical Laboratory, Saitama Medical Center. Samples of venous blood were collected in ethylenediamine tetraacetic acid (EDTA)-containing tubes from the brachial vein and centrifuged within 15 minutes to obtain serum. Serum total CO~2~ was measured within 15 minutes after centrifugation using an automated biochemical analyzer (JCA-BM6070; JEOL, Tokyo, Japan), as were the biochemical parameters hemoglobin, total protein, serum albumin, blood urea nitrogen, serum creatinine, sodium, potassium, chloride, calcium, phosphate, magnesium, and glucose. Serum total CO~2~ was determined by an enzymatic method using a commercial kit (Toyobo, Osaka, Japan).

Samples of venous blood for gas analyses were collected in a heparinized blood-gas syringe from the brachial vein simultaneously with samples for other blood tests. These samples were analyzed within 10 minutes to obtain values for pH and partial pressure of carbon dioxide (pCO~2~). Blood pH and pCO~2~ were measured using a blood-gas analyzer (Rapidlab-1265; Siemens Healthcare Diagnostics, Tarrytown, NY, USA). The HCO~3~^−^ concentration was calculated from measured pH and pCO~2~ using the Henderson--Hasselbalch equation \[[@b8-krcp-38-326]\]:
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The estimated glomerular filtration rate (eGFR) was calculated using a modified version of the Modification of Diet in Renal Disease formula set by the Japanese Society of Nephrology \[[@b9-krcp-38-326]\]:
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Statistical analyses
--------------------

Statistical analyses were performed using JMP v11 (SAS Institute, Cary, NC, USA). Data are the mean ± standard deviation for continuous variables and are count and percentage for categorical variables. Comparisons of component ratios among groups were performed using Fisher's exact test with the Bonferroni correction. Comparisons of clinical parameters among groups were performed using the Kruskal--Wallis test with the Steel--Dwass test. Correlations between two variables were evaluated by Pearson's correlation coefficient. Linear regression analysis was used to detect factors independently correlated with HCO~3~^−^ concentration. Parameters that significantly correlated with HCO~3~^−^ concentration in a simple linear regression analysis were included in a multiple linear regression analysis. An approximation formula involving serum total CO~2~ was determined using variables that independently correlated with HCO~3~^−^ concentration in the multiple linear regression analysis. The diagnostic accuracy of serum total CO~2~ and approximated HCO~3~^−^ concentration was examined using ROC curve analysis and a 2 × 2 table. The area under the curve (AUC), sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated for detection of low bicarbonate (HCO~3~^−^ \< 24 mmol/L) and high bicarbonate (HCO~3~^−^ ≥ 24 mmol/L). For all tests, *P* \< 0.05 was considered significant.

Results
=======

Patient characteristics
-----------------------

The characteristics of patients and their medications were categorized by CKD stage (G1 + G2, G3, G4, G5) ([Table 1](#t1-krcp-38-326){ref-type="table"}). A total of 305 blood samples from 207 patients (139 males, 68 females; mean age, 64.7 ± 16.1 years) was obtained. The number of patients for each CKD stage was 46 for G1 + G2, 50 for G3, 51 for G4, and 60 for G5.

There were significant differences in age as well as use of corticosteroid, β-blocker, loop diuretic, sodium bicarbonate, potassium binder, phosphate binder, or inhibitor of the renin--angiotensin system (RAS) among groups categorized by CKD stage. Age was significantly lower in patients with CKD stage G1 + G2 than those with CKD stage G3, G4, or G5 (*P* \< 0.001 for all).

The proportions of patients using a β-blocker (*P* \< 0.005, G1 + G2 vs. G4 and G5), RAS inhibitor (*P* \< 0.05, G1 + G2 vs. G4 and G5), loop diuretic (*P* \< 0.001, G1 + G2 vs. G3, G4, and G5), thiazide diuretic (*P* \< 0.005, G3 vs. G5), sodium bicarbonate (*P* \< 0.05, G5 vs. G1 + G2 and G3), potassium binder (*P* \< 0.01, G1 + G2 vs. G5), or phosphate binder (*P* \< 0.05, G5 vs. G1 + G2 and G3) increased significantly with CKD stage. The percentage of patients using a corticosteroid decreased with CKD stage (*P* \< 0.05, G1 + G2 vs. G5).

Correlation between serum total CO~2~ and HCO~3~^−^ concentration
-----------------------------------------------------------------

[Fig. 1](#f1-krcp-38-326){ref-type="fig"} shows the correlation between serum total CO~2~ and HCO~3~^−^ concentration in each group categorized by CKD stage. Serum total CO~2~ was correlated with HCO~3~^−^ concentration significantly and substantially in all patients (r = 0.91; *P* \< 0.001), patients with CKD stage G1 + G2 (r = 0.88; *P* \< 0.001), patients with CKD stage G3 (r = 0.84; *P* \< 0.001), patients with CKD stage G4 (r = 0.89; *P* \< 0.001), and patients with CKD stage G5 (r = 0.93; *P* \< 0.001).

Formula for approximation of HCO~3~^−^ concentration
----------------------------------------------------

A simple linear regression analysis showed that HCO~3~^−^ concentration was significantly negatively correlated with age, blood urea nitrogen, potassium, chloride, phosphate, blood glucose, and use of an RAS inhibitor, sodium bicarbonate, potassium binder, or phosphate binder. The HCO~3~^−^ concentration showed significant positive correlations with serum albumin, hemoglobin, eGFR, total calcium, serum total CO~2~, and use of a corticosteroid or aldosterone receptor antagonist. We performed a multivariate linear regression analysis using variables that showed a significant correlation with HCO~3~^−^ concentration in the simple linear regression analysis ([Table 2](#t2-krcp-38-326){ref-type="table"}). The multiple linear regression analysis revealed that serum albumin (*P* = 0.006), eGFR (*P* = 0.047), chloride (*P* \< 0.001), blood glucose (*P* = 0.004), and serum total CO~2~ (*P* \< 0.001) were independently correlated with HCO~3~^−^ concentration.

An approximated HCO~3~^−^ formula based on serum total CO~2~ was developed using variables that showed a significant correlation with HCO~3~^−^ concentration in the multiple linear regression analysis:
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Inputting the mean values of serum albumin, eGFR, chloride, blood glucose, and serum total CO~2~ into the model, the formula was simplified into a final version \[[@b10-krcp-38-326]\]:
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Correlation between approximated HCO~3~^−^ and measured HCO~3~^−^ concentrations
--------------------------------------------------------------------------------

[Fig. 2](#f2-krcp-38-326){ref-type="fig"} shows the correlation between approximated HCO~3~^−^ concentration calculated by our formula and measured HCO~3~^−^ concentration in each group categorized by CKD stage. The approximated HCO~3~^−^ concentration was significantly correlated with the measured HCO~3~^−^ concentration in all patients (r = 0.92; *P* \< 0.001), patients with CKD stage G1 + G2 (r = 0.90; *P* \< 0.001), patients with CKD stage G3 (r = 0.83; *P* \< 0.001), patients with CKD stage G4 (r = 0.91; *P* \< 0.001), and patients with CKD stage G5 (r = 0.94; *P* \< 0.001).

Diagnostic accuracy of serum total CO~2~ and approximated HCO~3~^−^ concentration for prediction of low bicarbonate and high bicarbonate levels
-----------------------------------------------------------------------------------------------------------------------------------------------

The ROC curves of serum total CO~2~ and approximated HCO~3~^−^ concentration for detecting low bicarbonate (HCO~3~^−^ \< 24 mmol/L) and high bicarbonate (HCO~3~^−^ ≥ 24 mmol/L) are shown in [Fig. 3](#f3-krcp-38-326){ref-type="fig"}. The AUCs of serum total CO~2~ and approximated HCO~3~^−^ concentration for detection of low bicarbonate and high bicarbonate were 0.981, 0.996, 0.993, and 1.000, respectively. The optimal cutoff values of serum total CO~2~ and approximated HCO~3~^−^ concentration for detection of low bicarbonate and high bicarbonate were 22.2 mmol/L, 23.2 mmol/L, 23.8 mmol/L, and 24.0 mmol/L, respectively. The 2 × 2 tables stratified by serum total CO~2~, the approximated HCO~3~^−^ concentration, and the measured HCO~3~^−^ concentration for low bicarbonate and high bicarbonate are shown in [Table 3](#t3-krcp-38-326){ref-type="table"}. The diagnostic accuracy values of serum total CO~2~ and approximated HCO~3~^−^ concentration for prediction of low bicarbonate and high bicarbonate are shown in [Table 4](#t4-krcp-38-326){ref-type="table"}. The sensitivity, specificity, positive predictive value, negative predictive value, accuracy, pre-test probability, positive post-test probability, and negative post-test probability were 91.7%, 73.4%, 72.5%, 92.0%, 81.3%, 43.3%, 72.5%, and 8.0% for serum total CO~2~ and 84.8%, 87.9%, 84.2%, 88.4%, 86.6%, 43.3%, 84.2%, and 11.6% for approximated HCO~3~^−^ concentration, respectively. The approximated HCO~3~^−^ concentration showed superior accuracy compared with that for serum total CO~2~ (86.6% vs. 81.3%).

Discussion
==========

We assessed the relationship between serum total CO~2~ and HCO~3~^−^ concentration in CKD patients who were not undergoing renal replacement therapy. This assessment enabled development of an approximation formula for prediction of low bicarbonate and high bicarbonate using clinical parameters involving serum total CO~2~.

Serum total CO~2~ is the total concentration of all forms of CO~2~ in a serum sample: HCO~3~^−^, carbonate, and dissolved CO~2~. In general, serum total CO~2~ value is approximately equivalent to the HCO~3~^−^ concentration because most of the CO~2~ in blood exists as HCO~3~^−^ \[[@b6-krcp-38-326]\]. Furthermore, serum total CO~2~ was shown to have a substantial correlation with HCO~3~^−^ concentration by Kumar and Karon \[[@b7-krcp-38-326]\]. However, a discrepancy between serum total CO~2~ and HCO~3~^−^ concentration caused by the influence of temperature and acidity \[[@b11-krcp-38-326]\] is occasionally observed in patients without renal impairment \[[@b12-krcp-38-326]\]. In the present study, serum albumin, eGFR, chloride, and blood glucose, in addition to serum total CO~2~, were independently associated with HCO~3~^−^ concentration in serum.

Increased serum albumin has been reported to be associated with metabolic acidosis in pre-dialysis CKD patients \[[@b13-krcp-38-326]\], and this phenomenon can be explained, at least in part, by the weak acidity of albumin \[[@b14-krcp-38-326]\]. These findings are consistent with our result showing a negative correlation between the concentrations of albumin and HCO~3~^−^ in serum. Furthermore, the HCO~3~^−^ concentration in serum decreases with progression of CKD stage \[[@b13-krcp-38-326]\], and this reduction has been suggested to be due to the inability of the kidney to synthesize ammonia, regenerate HCO~3~^−^, and excrete hydrogen ions (H^+^) \[[@b15-krcp-38-326]\]. Therefore, HCO~3~^−^ concentration was expected to have a positive correlation with eGFR. However, in the present study, HCO~3~^−^ concentration was negatively correlated with GFR. This difference between our result and those of published reports may be explained by the increase in the ratio of use of diuretics and sodium bicarbonate with progression of CKD stage because such use leads to an increase in HCO~3~^−^ concentration in serum \[[@b13-krcp-38-326],[@b16-krcp-38-326]\]. Loop diuretics and thiazide diuretics inhibit the Na^+^-K^+^-2Cl^−^ cotransporter and Na^+^-Cl^−^ cotransporter, respectively, and increase sodium delivery to distal tubular segments. The delivered sodium is reabsorbed at cortical collecting ducts due to, at least in part, the increase of serum aldosterone induced by diuretic-associated reduction of intravascular fluids \[[@b17-krcp-38-326]\]. Furthermore, an increase in serum aldosterone associated with diuretic use stimulates H^+^-ATPase activity at cortical collecting ducts \[[@b18-krcp-38-326]\], which leads to an increase in HCO~3~^−^ concentration in serum. An increase in serum aldosterone also stimulates potassium excretion at cortical collecting ducts, which leads to a decrease in serum potassium concentration \[[@b19-krcp-38-326]\]. A decreased serum potassium concentration may increase renal production of ammonia and excretion of ammonium ions, which result in an increase in HCO~3~^−^ concentration in serum \[[@b20-krcp-38-326]\]. In addition, sodium bicarbonate is administered frequently in CKD patients with metabolic acidosis. Therefore, use of diuretics and sodium bicarbonate may reflect the inverse relationship between changes in eGFR and HCO~3~^−^ concentration in serum noted in our study. However, further studies in a much larger cohort are needed to confirm the relationship between these factors.

Hyperchloremic metabolic acidosis is observed in 30% to 50% of patients with chronic renal failure \[[@b21-krcp-38-326]\]. The chloride concentration in serum has been reported to increase as HCO~3~^−^ concentration in serum decreases \[[@b22-krcp-38-326]\]. We documented a negative correlation between chloride and HCO~3~^−^ concentrations in serum with progression of CKD stage, a finding that is compatible with that of Widmer et al \[[@b22-krcp-38-326]\]. Blood glucose was negatively correlated with HCO~3~^−^ concentration in serum in the present study. Uremia inhibits insulin secretion as well as insulin sensitivity \[[@b23-krcp-38-326]\], which leads to an increase in blood glucose concentration with metabolic acidosis via reduction in Na^+^/H^+^ exchanger activity \[[@b24-krcp-38-326]\]. Glucose appears in urine if the blood glucose concentration exceeds the renal threshold of 170 to 200 mg/dL \[[@b25-krcp-38-326]\]. Increased urinary glucose has been shown to inhibit H+ excretion through proximal renal tubules \[[@b26-krcp-38-326]\] and activates the sodium--glucose-coupled transporter, which inhibits the Na^+^-H^+^ exchanger via competition for sodium influx. The subsequent decreased H^+^ excretion leads to metabolic acidosis with a reduction of HCO~3~^−^ concentration in plasma \[[@b27-krcp-38-326]\]. Therefore, our findings may be explained by data reported previously.

Measurement of serum total CO~2~ has two main advantages compared with blood-gas analyses. First, the cost of a blood-gas syringe can be saved, and the amount of blood collected is reduced. Second, serum total CO~2~ can be used to predict metabolic acidosis and metabolic alkalosis without use of a blood-gas analyzer. Therefore, measurement of serum total CO~2~ would alleviate some of the burden on patients and laboratory staff. In addition, the approximated HCO~3~^−^ concentration derived from clinical parameters, including serum total CO~2~, could have been useful for predicting disturbances of acid--base metabolism in the present study.

Our study had four main limitations. First, this was a single-center, retrospective, observational study and may have been subject to bias in patient selection. Second, the study cohort was small, which limits the generaliz-ability of our findings. Third, several baseline characteristics, including age and medication use, were significantly different among groups categorized by CKD stage. Fourth, we used venous blood samples for analyses. The results might have been different if samples of arterial blood had been used. However, pH and HCO~3~^−^ have been reported to show sufficient agreement between arterial and venous blood-gas analysis \[[@b28-krcp-38-326]\]. Therefore, further prospective, large-scale, multicenter studies with arterial blood samples for gas analysis are required to confirm our findings.

In conclusion, serum total CO~2~ was substantially correlated with HCO~3~^−^ concentration in the serum of pre-dialysis CKD patients. An approximation formula including serum total CO~2~ showed superior diagnostic accuracy for low and high bicarbonate levels compared with serum total CO~2~.
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###### 

Comparison of patient characteristics and medications according to chronic kidney disease (CKD) stage

  CKD stage                             All           G1 + G2         G3            G4            G5              *P* value
  ------------------------------------- ------------- --------------- ------------- ------------- --------------- ------------------------------------------------------------------------------
  Number of patients                    207           46              50            51            60              
  Number of samples                     305           59              65            70            111             
  Age (yr)                              64.7 ± 16.1   49.2 ± 18.1\*   68.0 ± 11.5   71.1 ± 12.1   68.4 ± 13.4     \**P* \< 0.001 vs. G3, G4 and G5
  Male                                  139 (67.1)    24 (52.2)       35 (70.0)     37 (72.5)     43 (71.7)       
  Body mass index (kg/m^2^)             23.8 ± 5.1    23.4 ± 4.8      24.1 ± 5.1    23.6 ± 3.8    24.0 ± 6.3      
  Diabetes mellitus                     75 (36.2)     9 (19.6)        20 (40.0)     22 (43.1)     24 (40.0)       
  Corticosteroid                        30 (14.5)     13 (28.3)       9 (18.0)      5 (9.8)       3 (5.0)\*       \**P* \< 0.05 vs. G1 + G2
  β-blocker                             46 (22.2)     1 (2.2)         7 (14.0)      15 (29.4)\*   23 (38.3)\*\*   \**P* \< 0.005 vs. G1 + G2, \*\**P* \< 0.001 vs. G1 + G2, *P* \< 0.05 vs. G3
  Renin--angiotensin system inhibitor   131 (63.3)    19 (41.3)\*     31 (62.0)     38 (74.5)     43 (71.7)       \**P* \< 0.01 vs. G4, *P* \< 0.05 vs. G5
  Aldosterone receptor antagonist       7 (3.4)       1 (2.2)         2 (4.0)       3 (5.9)       1 (1.7)         
  Loop diuretics                        64 (30.9)     0 (0.0)\*       14 (28.0)     19 (37.3)     31 (51.7)       \**P* \< 0.001 vs. G3, G4, and G5
  Thiazide diuretics                    16 (7.7)      2 (4.3)         0 (0.0)       2 (3.9)       12 (20.0)\*     \**P* \< 0.005 vs. G3
  Sodium bicarbonate                    37 (17.9)     2 (4.3)         6 (12.0)      7(13.7)       22 (36.7)\*     \**P* \< 0.001 vs. G1 + G2, *P* \< 0.05 vs. G3
  Potassium binder                      23 (11.1)     1 (2.2)         3 (6.0)       5 (9.8)       14 (23.3)\*     \**P* \< 0.01 vs. G1 + G2
  Phosphate binder                      10 (4.8)      0 (0.0)         0 (0.0)       1 (2.0)       9 (15.0)\*      \**P* \< 0.05 vs. G1 + G2 and G3

Data are presented as number only, mean ± standard deviation, or number (%).

###### 

Simple and multiple linear regression analyses of the variables correlated with HCO~3~^−^ concentration

  Variable                                                  Simple linear regression analysis   Multivariate linear regression analysis                     
  --------------------------------------------------------- ----------------------------------- ----------------------------------------- -------- -------- ----------
  Constant                                                                                                                                23.070            
  Age (yr)                                                  −0.036                              0.017                                     −0.005   −0.019   0.50
  Male (yes vs. no)                                         −0.913                              0.08                                                        
  Body mass index (kg/m^2^)                                 −0.060                              0.18                                                        
  Diabetes mellitus (yes vs. no)                            0.105                               0.83                                                        
  Corticosteroid (yes vs. no)                               2.261                               \< 0.001                                  −0.011   −0.001   0.97
  β-blocker (yes vs. no)                                    −0.878                              0.11                                                        
  Renin--angiotensin system inhibitor (yes vs. no)          −1.568                              0.002                                     0.015    0.002    0.94
  Aldosterone receptor antagonist (yes vs. no)              2.857                               0.033                                     −0.185   −0.008   0.73
  Loop diuretic (yes vs. no)                                0.081                               0.87                                                        
  Thiazide diuretic (yes vs. no)                            0.450                               0.54                                                        
  Sodium bicarbonate (yes vs. no)                           −3.287                              \< 0.001                                  −0.455   −0.043   0.08
  Potassium binder (yes vs. no)                             −1.889                              0.007                                     0.022    0.002    0.94
  Phosphate binder (yes vs. no)                             −3.472                              \< 0.001                                  0.298    0.019    0.45
  Total protein (g/dL)                                      1.009                               0.003                                                       
  Serum albumin (g/dL)                                      1.464                               \< 0.001                                  −0.559   −0.077   0.006
  Hemoglobin (g/dL)                                         0.800                               \< 0.001                                  0.078    0.042    0.19
  Blood urea nitrogen (mg/dL)                               −0.050                              \< 0.001                                  −0.012   −0.080   0.06
  Creatinine (mg/dL)                                        −0.702                              \< 0.001                                                    
  Estimated glomerular filtration rate (mL/min/1.73 m^2^)   0.047                               \< 0.001                                  −0.009   −0.069   0.047
  Uric acid (mg/dL)                                         −0.052                              0.28                                                        
  Sodium (mmol/L)                                           −0.011                              0.89                                                        
  Potassium (mmol/L)                                        −3.587                              \< 0.001                                  −0.227   −0.029   0.28
  Chloride (mmol/L)                                         −0.480                              \< 0.001                                  −0.145   −0.172   \< 0.001
  Total calcium (mg/dL)                                     2.360                               \< 0.001                                  0.133    0.024    0.42
  Phosphate (mg/dL)                                         −1.240                              \< 0.001                                  −0.064   −0.020   0.59
  Magnesium (mg/dL)                                         0.154                               0.83                                                        
  Blood glucose (mg/dL)                                     −0.011                              0.047                                     −0.007   −0.072   0.004
  Serum total CO~2~ (mmol/L)                                1.009                               \< 0.001                                  0.859    0.777    \< 0.001

CO~2~, carbon dioxide; HCO~3~^−^, bicarbonate ion.

###### 

2 × 2 tables stratified by serum total CO~2~, approximated HCO~3~^−^ concentration and measured HCO~3~^−^ concentration for low bicarbonate (HCO~3~^−^ \< 24 mmol/L) and high bicarbonate (HCO~3~^−^ ≥ 24 mmol/L)

                                                                      HCO~3~^−^   Total   
  ------------------------------------------------------------------- ----------- ------- -----
  Serum total CO~2~                                                                       
   Low serum total CO~2~ (serum total CO~2~ \< 24 mmol/L)             121         46      167
   High serum total CO~2~ (serum total CO~2~ ≥ 24 mmol/L)             11          127     138
  Total                                                               132         173     305
  Approximated HCO~3~^−^                                                                  
   Low approximated HCO~3~^−^(approximated HCO~3~^−^ \< 24 mmol/L)    112         21      133
   High approximated HCO~3~^−^ (approximated HCO~3~^−^ ≥ 24 mmol/L)   20          152     172
  Total                                                               132         173     305

CO~2~, carbon dioxide; HCO~3~^−^, bicarbonate ion.

###### 

Comparison of diagnostic values between serum total CO~2~ and approximated HCO~3~^−^

                                       Serum total CO~2~   Approximated HCO~3~^−^
  ------------------------------------ ------------------- ------------------------
  Sensitivity (%)                      91.7                84.8
  Specificity (%)                      73.4                87.9
  Positive predictive value (%)        72.5                84.2
  Negative predictive value (%)        92.0                88.4
  Accuracy (%)                         81.3                86.6
  Pre-test probability (%)             43.3                43.3
  Positive post-test probability (%)   72.5                84.2
  Negative post-test probability (%)   8.0                 11.6

CO~2~, carbon dioxide; HCO~3~^−^, bicarbonate ion.

[^1]: Edited by Sejoong Kim, Seoul National University, Seoul, Korea
